Junsai Bio Launches World's Largest and Most Advanced TIL Cell Industrialization Base in Shanghai

The New Quality TIL Cell Industrialization Base of Juncell Therapeutics houses the production center, quality center, data center, and operations center, with a total area exceeding 16,000 square meters and a designed capacity of 6,000 to 10,000 cases per year. The completion of the base marks another significant milestone for Juncell Therapeutics following the approval of GC101, the world's first TIL cell drug that does not require lymphodepletion or IL-2 injection, for pivotal Phase II clinical trials. This will strongly promote the development of high-quality TIL products and accelerate the transformation of disruptive innovative technologies into new biomedical productivity.

Zhou Hanmin, Standing Committee Member of the Chinese People's Political Consultative Conference (CPPCC) and President of the Shanghai Public Diplomacy AssociationThe speech noted that the biopharmaceuticals industry is a strategic emerging industry, holding immense potential for development. It represents the industry of the future and is also a blue ocean industry.TIL Cell Therapy Belongs to the High-end and Precise Medical Project, and is a Typical Representative of New Quality Productivity in the Biomedical Field.The completion of Juncell Therapeutics' new TIL cell industrialization base will strongly promote the development of the TIL cell industry, benefit cancer patients, and create greater social and economic benefits.

Lu Zufang, Standing Committee Member of Jiading District Party Committee and Executive Deputy District ChiefIn his speech, he noted that the successful completion of Juncell Therapeutics' new TIL cell industrialization base is an important achievement of mutual trust, cooperation, and joint efforts between the two levels of government in Jiading District, Shanghai, and Juncell Therapeutics.It is exciting to see Juncell Therapeutics, starting from the perspective of "unmet clinical needs," pursue independent innovation, demonstrate bold progress, and strive to reach new heights in the treatment of solid tumors.We look forward to Juncell Therapeutics building on this opportunity, making continued efforts to accelerate the cultivation and development of the new TIL industry, serving cancer patients, and contributing to the high-quality development of the biopharmaceuticals industry in Jiading District and even Shanghai.

Sun Pengjun, Chairman of Fudan Science and Innovation Fund and Chairman & General Manager of Shanghai Furon Investment Co., Ltd., Fei Jianjiang, Founding Partner of Yuanhe Origin, He Shaojun, Chairman of Wuhan University Shanghai Alumni Association and Founding Chairman of Shanghai Oriental Yuhong Waterproof Technology Co., Ltd.All expressed congratulations on the completion of the base and conveyed high hopes for the next stage of development of Juncell Therapeutics.

Jin Hua Jun, Ph.D., Founder of Juncell TherapeuticsWe would like to express our heartfelt gratitude to all the leaders and guests attending the ceremony. We would also like to express that the company started in Jiading and has grown in Jiading, receiving care and support from governments at the city, district, and town levels along the way, as well as support and assistance from all sectors. Currently, the first TIL product, GC101, has entered the critical Phase II and is expected to be launched in 2026; the world's first non-viral vector gene-modified TIL, GC203, has enteredClinical IThe products are expected to be launched in 2027. Both have demonstrated excellent clinical safety and efficacy.

Subsequently, Dr. Jinhua Jun, accompanied all the distinguished guests on a field tour of the company's new TIL cell industrialization base. The guests showed great interest in the CGT-specific elements visible throughout the facility, highly praised the human-centric and eco-friendly design concepts integrated throughout, and commended the company for its focus on product quality and its forward-thinking, high-standard, and rigorous planning. They expressed their hope that the company would continue to enhance the quality of its software and hardware, making this base a model for the cell therapy industry.

The completion of the New Quality TIL Cell Intelligent Manufacturing Base marks the starting point of Juncell Therapeutics' "Intelligent Manufacturing Leadership" journey. The company will continue to focus on patients, prioritize clinical value, and consistently develop high-quality TIL products in China for global benefit.